Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 92,563,384
  • Shares Outstanding, K 1,103,390
  • Annual Sales, $ 21,222 M
  • Annual Income, $ 2,738 M
  • 36-Month Beta 0.36
  • Price/Sales 4.38
  • Price/Cash Flow 17.79
  • Price/Book 6.60

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.75 +7.70%
on 05/30/17
84.76 -1.21%
on 06/22/17
+5.68 (+7.28%)
since 05/26/17
3-Month
76.85 +8.96%
on 05/22/17
86.72 -3.44%
on 04/05/17
-0.50 (-0.60%)
since 03/27/17
52-Week
64.18 +30.47%
on 11/23/16
86.72 -3.44%
on 04/05/17
+8.85 (+11.81%)
since 06/27/16

Most Recent Stories

More News
Fight Colorectal Cancer Launches Biomarked to Educate on the Role of Biomarkers in Cancer Treatment

Today, Fight Colorectal Cancer (Fight CRC), the leading patient advocacy group in colorectal cancer, kicked-off Biomarked, with support from Eli Lilly and Company, to shine a spotlight on genetic biomarkers...

LLY : 83.55 (-0.87%)
Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour

For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, "you are not alone." Lilly...

LLY : 83.55 (-0.87%)
Biopharmaceuticals Market Active Key Players Are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer and Eli Lilly

Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022

JNJ : 135.85 (-0.36%)
LLY : 83.55 (-0.87%)
AMGN : 173.63 (-0.02%)
Global Diabetes Injection Pens Market to Reach $10.7 Billion by 2025 - Analysis By Indication, Product Type, Form & Geography

Research and Markets has announced the addition of the "Global Diabetes Injection Pens Market, 2017 to 2025" report to their offering. The global diabetes injection pens market was valued at US$ 5.6 Bn...

NVO : 43.84 (-1.24%)
LLY : 83.55 (-0.87%)
Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

LLY : 83.55 (-0.87%)
NVS : 86.10 (+0.41%)
REGN : 519.19 (+0.64%)
GSK : 43.96 (-0.25%)
Why You Should Add Novo Nordisk Stock to Your Portfolio

Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

NVO : 43.84 (-1.24%)
MRK : 65.87 (-0.08%)
LLY : 83.55 (-0.87%)
SNY : 49.39 (-0.40%)
Merck's Keytruda on a Roll: Can it Retain the Momentum?

As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma...

MRK : 65.87 (-0.08%)
LLY : 83.55 (-0.87%)
AMGN : 173.63 (-0.02%)
PFE : 33.89 (-0.44%)
Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion

Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk...

AZN : 34.73 (-1.19%)
NVO : 43.84 (-1.24%)
MRK : 65.87 (-0.08%)
LLY : 83.55 (-0.87%)
Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego

Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery...

LLY : 83.55 (-0.87%)
Global Head and Neck Cancer Treatment Market to Grow at a CAGR of 8% by 2021 - Key Vendors are Bristol-Myers Squibb, Eli Lilly, Merck & Pfizer - Research and Markets

Research and Markets has announced the addition of the "Global Head and Neck Cancer Treatment Market 2017-2021" report to their offering.

MRK : 65.87 (-0.08%)
LLY : 83.55 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research...

See More

Support & Resistance

2nd Resistance Point 84.92
1st Resistance Point 84.60
Last Price 83.55
1st Support Level 83.81
2nd Support Level 83.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.